Join Our Newsletter
Get the best of VaccineNation in your inbox
Stay informed. Get the newsletter that gives you an edge in this rapidly changing sector, for free.
MOST POPULAR THIS MONTH
African leaders vow to end AIDS in children by 2030
At the first ministerial meeting of the Global Alliance to end AIDS in children, leaders from 12 African countries discussed their commitments to ending AIDS in children by 2030. The meeting took place in the United Republic of Tanzania, in Dar es Salaam. A WHO...
IVAC runs vaccine hesitancy training course in India
In December 2022 the International Vaccine Access Centre was able to conduct a test run of its newly developed training course on vaccine hesitancy. With a grant from the Sabin Vaccine Institute the course is aimed at healthcare workers, who can take it online or in...
The 100 days mission: UKHSA assumes responsibility
Of the many lessons that we are endeavouring to learn from the COVID-19 pandemic, the importance of uniting speed with safety is one of the most obvious. With this in mind, in 2021, the world embarked on a joint “mission” to arm ourselves against future threats within...
Cancer vaccines strengthened against aggressive tumours
In research published in Nature biomedical engineering a team of scientists at Northwestern University’s International Institute for Nanotechnology (IIN) explored the effects of structural changes to cancer vaccines. Using chemistry and nanotechnology they changed the...
World Vaccine Congress Washington: meet our start-ups!
Following our previous posts, moving through the start-up zone at the World Vaccine Congress in Washington at speed, we are excited to share a further update: P-N of the start-up zone. If you are interested in joining your colleagues in the start-up area, please make...
Moderna secures FDA Breakthrough Therapy Designation for RSV
Moderna announced in January 2023 that its investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), mRNA-1345, has been granted Breakthrough Therapy Designation by the US FDA. The designation was based on the positive data from the ConquerRSV...
White paper from IAVI: vaccine partnerships for EIDs
In January 2023 IAVI released a white paper after a meeting between global health experts. As a result of a convergence of several diseases in 2022, mpox, ebolavirus, and COVID-19, IAVI and the Rockefeller Foundation established the meeting: “delivering vaccines for...
Marburg vaccine candidate shows in-human promise
A study in The Lancet with NIH funding reported that a vaccine candidate against Marburg virus (MARV) was safe and induced and immune response in a limited, first-in-human trial. Developed by researchers at NIAID, this experimental vaccine “could someday be an...
